SAMPLE - MSFHR · SAMPLE. Grant ID: 17616. Applicant: Andrew. Tester. Host Institution: MSFHR-DO...

Grant ID: 17616Applicant: Andrew Tester

Host Institution: MSFHR-DO NOT USECompetition: 2018 Scholar Competition

Task: Complete Full Application (CIA)Submitted: 11/1/2017 9:59:44 AM

1 | P a g e

CONTACT INFORMATION

Name Mr. Andrew Philippe Tester

Organization Affiliations

MSFHR-DO NOT USE

E-mail Address [email protected]

Address1234 Test Avenue

Vancouver, BC V1V 1V1

Phone 123-456-7890 Ext. 321

Degrees MPH, MSFHR University, 2009,

Web Address

Health Professional No - N/ASAMPLE




2 | P a g e

HOST INSTITUTION

Host Institution

Primary Role Organization City Country

Yes Host Institution MSFHR-DO NOT USE Vancouver Canada

Research Location

Role Organization City Country

Research LocationBC Cancer Agency – Vancouver

SAMPLE




3 | P a g e

PROJECT INFORMATION

Project Title Lorem Ipsum

Brief Description Character Limit: 1250 characters

Scientific Summary Character Limit: 1250 characters

SAMPLE




4 | P a g e

THEME AND KEYWORDS

Theme Biomedical

Category SCH

Keywords Aboriginal Health, Abortion, Adaption of Interventions, Adolescent Health, Aging

SAMPLE




5 | P a g e

THIRD PARTY

Applicant

Primary Role Name Organization Name

Yes Scholar Andrew Tester, Philippe MSFHR-DO NOT USE

Third Party

Role Name Organization Name

Dean First Tester, BC Cancer Foundation

Department Head Second Tester, MSFHR-DO NOT USE

Reference Third Tester MSFHR-DO NOT USE

Reference Fourth Tester, University of British Columbia –Vancouver Campus

Reference Fifth Tester, MSFHR-DO NOT USE

SAMPLE




6 | P a g e

BC HEALTH SYSTEM PRIORITIES 2018

Is your current program of research related to any of the following BC health system priority areas?

1. Primary and community care NotRelated

2. Services for patients with complex medical conditions and/or frail patients (including dementia)

Secondary

3. Mental health and/or substance use Secondary

4. Surgical services (including perioperative services) Secondary

5. Rural and remote health care services Secondary

Is your current program of research related to Indigenous health?

1. Indigenous health (including First Nations health) Secondary

Briefly describe how your program of research addressesthe BC health system priority area(s).

Character limit: 2000 characters

CAREER INTERRUPTIONS

1. Have you experienced any career interruptions? Yes

Career Interruption 1

2. Career Interruption 1 Start Date 11/1/2007

3. Career Interruption 1 End Date 9/30/2008

4. Career Interruption 1 Description Character limit: 2000 characters

5. Career Interruption 1 Duration, in months


6. Career Interruption 2 Start Date

7. Career Interruption 2 End Date

8. Career Interruption 2 Description






SAMPLE




7 | P a g e







SAMPLE




8 | P a g e

ADDITIONAL INFORMATION

Response to Previous Reviews

If you were unsuccessful in applying to the MSFHR Scholar Program in the past, please provide a response to your previous reviews. If this is your first time applying, please enter "Not Applicable" in the text box below.

Character Limit: 5000 characters

Most Significant Contribution(s)

Identify a maximum of five contributions that best highlight your most significant contributions to research, defining the impact and relevance of each. A contribution can be a publication, presentation, patent or intellectual property right, knowledge translation activity, policy development, contract, etc. Your complete description must include the organization; position or activity type and description; start and end dates; target audience, and the basis on which this contribution is significant.


Knowledge Translation

If the single research project and/or the program of research is fully focused on KT science, please provide a briefstatement on how it aligns with MSFHR's definition of KT science. Visit (http://www.msfhr.org/our-work/activities/knowledge-translation) for additional information and sample study protocols specific to KT science(http://www.msfhr.org/our-work/activities/knowledge-translation/kt-resources/kt-science-sample-study-protocols). KT science research projects are evaluated under specific KT science evaluation criteria.


UPLOADS

The following pages contain the uploads provided by the applicant:

Upload Type File Name Uploaded By Uploaded Date

SAMPLE

http://www.msfhr.org/our-work/activities/knowledge-translation

http://www.msfhr.org/our-work/activities/knowledge-translation/kt-resources/kt-science-sample-study-protocols




9 | P a g e

MSFHR Full CCV MSFHR Full CCV.pdf Biagtan, Andrew 11/01/2017

Pubs, Patents & Intellectual Rights

Pubs, Patents & Intellectual Rights.pdf

Biagtan, Andrew 11/01/2017

Program of Research& Appendices

Program of Research & Appendices.pdf

Biagtan, Andrew 11/01/2017

SAMPLE

Ms. Dainty Sales

1

Protected when completed

Date Submitted: 2013-11-08 16:32:11Confirmation Number: 171612Template: Career Annual Report CV

Personal InformationIdentification

Ms. Dainty SalesCorrespondence language: EnglishSex: FemaleDate of Birth: 1/28Canadian Residency Status: Canadian Citizen

AddressThe primary address is denoted by (*)

Primary Affiliation (*)

Michael Smith Foundation forHealth Research1285 West BroadwayVancouverV6H 3X8Canada, British Columbia

TelephoneThe primary telephone is denoted by (*)

Fax 1-604-555-1234

(*) 1-604-7146601

EmailThe primary email is denoted by (*)

(*) [email protected]

User ProfileResearcher Status: ResearcherResearch Career Start Date: 2000-12-12Engaged in Clinical Research?: No

SAMPLE

Ms. Dainty Sales

2

Employment

Leaves of Absence and Impact on ResearchAdministrative

Research Funding History

* - Scholarship

Activities

Assessment and Review Activities

Journal Review Activities*

Conference Review Activities*

Community and Volunteer Activities*

Knowledge and Technology Translation*

International Collaboration Activities*

Memberships

Committee MembershipsChair

Other Memberships*

Contributions

Presentations"*",

SAMPLE

Ms. Dainty Sales

3

Publications

PubMed ArticlesPubMed ID: *

Journal Articles"*",

Journal Issues"*",

Books"*",

Book Chapters"*",

Book Reviews"*",

Translations"*",

Dissertations"*"

Supervised Student Publications*, ,

Litigations"*",

Newspaper Articles"*",

Newsletter Articles"*",

Encyclopedia Entries"*",

Magazine Entries"*",

SAMPLE

Ms. Dainty Sales

4

Dictionary Entries"*",

Reports"*"

Working Papers"*"

Manuals"*",

Online Resources"*"

Tests"*"

Clinical Care Guidelines"*"

Conference PublicationsPaper ,,

Intellectual Property

Patents*,

Licenses*

Disclosures*

Registered Copyrights*

Trademarks*

SAMPLE

Publication List

Abstracts:ffi'"fiT, FitzGerald JM, Fox N, Ryan cF, Marra c, Koehoorn M, Jung D,

chambers K, Fleetham J. Work Productivity and occup-ational tniuries in Patients

with Obstruct¡vi Steep Apnea Hypopnea. Submitted, ATS meeting 2004'

2) Patel sR, white DP, Malhotra A, Stanchina M, Ayas NT. Ihe Effect of 2PAP

Therapy on Suø¡áciivà and Obiective S/eeprness in Oø9t1t19tiu^e-S-leep Apnea: A

M et a- a'n a ty s¡ s íf R a n d o m i ze d' C o ntrotl e d T ri at s' S leep 2002', 25 : A 1 8'

3) Ayas NT, White DP, Manson JE, Stampfer MJ, Speizer FE, Ma|hotra A, Hu F. A

prospective stuly of Steep Duration and Coronary Heart Drsease in Women' Sleep

2002',25:A1Q7 .

4) Tachibana N, Ayas NT, White DI A Comparison of Sleep Laboratory Activity in the

lJnited Sfafes and Japan Sleep 20Q2;25:A47 '

5) Pittman sD, Pillar G, Ayas NT, Suraiya s, Malhotra.A,.White DP' Can Obstructive

s/eep Apnea øe oiagnosed in the Home lJsing a wrist-mounted Device with

Automated Anatysis-of Peripherat Arteriat Tonometry, Pulse oximetry, and

ActigraPhY? SleeP 2OO2', 25 -A42'

6) Stanchina M, Malhotra A, Fogel RB, Ayas NT, Edwards JK, Schory K, White DP'

The tnftuenr" oi Cnunging Litng Votlume on Genioglossus Muscle Activation andpharyngeal Mechanics Ouring Ñnef¿ S/eep. Sleep 2002;25:A135.

7) Sutherland ER, Allmers H, Ayas N, Venn AJ, Zello-s-L' Martin RJ' lnhaled

Corficosteroids tmprove The-Accelerated Dectine Of Fevt tn Patients W¡th COPD - A

Meta-Anatysis of b Triats. Am J Respir Crit Care Med 2002',165:A225'

8) MalhotraA, Lazic sE, Fogel RB, Stanchina M, Ayas N, White DP. Sfrucfural And

Functional Differences tn-The Llpper Airway Between Premenopausal And

Postmenopausalwomen. Am J Respir crit care Med 2002; 165:4799'

9) Stanchina M, Malhotra A, Fogel RB, Ayas NT, Edwards JK, Schory K, White DP'

The tnftuence of Changing Lltng Voilume on Genioglossus Muscle Activation andpharyngeat Coi6p,s¡i¡iít."Ourin-g NREM S/eep. Am J Respir Crit Care Med 2002''

165:439.

10)Ayas NT, Nuqent E, Mathew J, Epstein LJ, Malhotra A, White DP' Predictors of'

S]ø¡ective ofiinte S/eeprness in a Sleep Ctinic Poputation Am J Respir Crit Care

Med 2002; 165:4510.

11) Ayas NT, Pittman SD, Malhotra A, Pil lar G, Stanchina M, Winkelman J, White DP'prediction of Daytime S/eeprness using lndices of Autonomic Arousal. Am J Respir

Crit Care Med 2002; 165:4231.

12)Patel SR, Ayas N, Hess D, Kacmarek R, Thompson BT, Wain J, Malhotra A' The

Ut;t;ty of Open Lung Biopsy in Patients with the Acute Respiratory Disfress

SAMPLE

The information from this larqe studv will be important in terms of quantifvinq the public health and

Therefore, a comprehensive knowledge dissemination/translation component has also been included inthis proposal.

In the near future, blood collection and physiologic studies wil l be added to our registry; we wil l thendetermine the impact of OSAH on physiologic and biochemical indices known to be risk factors forcardiovascular disease (eg. C reactive protein, brachial artery endothelial function, 24 hour bloodpressure) and identify the genetic determinants of OSAH.

2. CRITIGAL REVIEW OF EXISTING LITERATURE:What is Obstructive Sleep Apnea Hypopnea? OSAH is characterized by recurrent nocturnalasphyxia due to recurrent collapse of the upper airurray during sleep. Loss of muscle tone of the upperairway dilators (particularly the tongue/genioglossus muscle) with sleep superimposed. on ananatomically susceptible upper ainruay results in recurrent pharyngeal collapse.l This results inrepetitive discrete episodes of decreased (obstructive hypopnea) or absent (obstructive apnea) aiÍlow,and nocturnal hypoxemia. Termination of these events requires arousal from sleep to reestablish upperairway tone, eliminate obstruction and allow ventilation to resume.

The repetitive episodes of asphyxia and sleep fragmentation lead to a myriad of adverse healthconsequences. First, sleep fragmentation leads to poor quality sleep, excessive daytime sleepiness,reduced vigilance, microsleeps, and neurocognitive dysfunction2. Second, the recurrent nocturnalarousals and hypoxemia results in activation of the sympathetic nervous system and systemicinflammation;t accumulating data implicate OSAH in thé pathogenesis of caid¡ovascular disease,including hypertension and cerebrovascular disease.a

OSAH is usually diagnosed by a sleep study (polysomnogram, PSG). This test is considered thegold standard for diagnosing OSAH, and consists of an overnight stay in the sleep laboratory with thecollection of multiple physiologic signals (e.g. airf low, depth of sleep, oxygen saturation,chest/abdominal movements) allowing precise assessment of disease severity. Disease severity isclassified according to the apnea hypopnea index, AHI (the number of t imes the- airway closes ornarrows per hour of sleep). By consensus criteria; an AHI of <5 events/hr of sleep is considerednormal, an AHI between 5-15 is considered mild disease, an AHI of 15-30 is considered moderatedisease, and an AHI of greater than 30 is considered severe.s

OSAH is common and underdiaqnosed. In a random population based sample of 602 individualsaged 30 to 60 years, an AHI of >5 was found in 24o/o of men and 9% of women.6 Moderate to severe

sociated with

disease (AHl >15) was found in g% of men and 4% of women. OSAH syndrome (i.e. AHI>5 withsymptoms of excessive daytime sleepiness) was found in 4% of men and 2%o of women. Sim¡láilv, ¡t ¡sestimated that approximately 25% of Canadian grain workers have sleep apnea.T Approximatetf OOV.of women and 80% of men with moderate to severe sleep apnea have not been clinically diagnosêd.8

Nasal continuous positive airway pressure (CPAP) therapy is considered first line treãtment forOSAH.e CPAP consists of a portable electric device attached io a nasal mask via plastic tubing. Byestablishing a positive pressure in the pharynx during sleep, CPAP prevents the upper ainruay fromcollapsing. CPAP is extremely effective in eliminating sleep fragmentation and preserving noåturnaloxygenation, thereby^improving daytime sleepiness, quality of l i fe, and neurocognitiveJunction inpatients with OSAH.'u One of the maior impediments to CPAP effectiveness is pátient compliance.Adherence with CPAP ranges from 50% to75o/o, and subjective reporls underestimate actual use.1,

Given the hiqh disease þrevalence, the overall public health and safetv impact of OSAH could b.immense. Patients with OSAH may have reduced work productivfiiñã bããt increased risk of motorvehicle crashes and occupational injuries. Furthermore, becauðe CPAP is effective in reducingsleepiness and improving neurocognitive function, CPAP should improve work productivity and reduce

SAMPLE

SAMPLE - MSFHR · SAMPLE. Grant ID: 17616. Applicant: Andrew. Tester. Host Institution: MSFHR-DO...

Documents

Transcript of SAMPLE - MSFHR · SAMPLE. Grant ID: 17616. Applicant: Andrew. Tester. Host Institution: MSFHR-DO...